Veeda Clinical Research IPO Details
| IPO Open Date | 2025 |
| IPO Close Date | 2025 |
| Face Value | ₹2 Per Equity Share |
| IPO Price Band | ₹[.] to ₹[.] Per Share |
| Issue Size | Approx ₹[.] Crores |
| Fresh Issue | Approx ₹[.] Crores |
| Offer for Sale: | Approx [.] Equity Shares |
| Issue Type | Bookbuilding Issue |
| IPO Listing | BSE, NSE |
| DRHP Draft Prospectus |  |
| RHP Draft Prospectus | |
Veeda Clinical Research IPO Review & Key Points
- Review:
Veeda Clinical Research IPO Market Lot
The Veeda Clinical IPO minimum market lot is [.] shares with ₹[.] application amount. The retail investors can apply up-to 13 lots with [.] shares of ₹[.] amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | – | – | ₹- |
| Retail Maximum | – | – | ₹- |
| S-HNI Minimum | – | – | ₹- |
| S-HNI Maximum | – | – | ₹- |
| B-HNI Minimum | – | – | ₹- |
IPO Reservation
| Investor Category | Share Offered | -% Shares |
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 75% |
| NII Shares Offered | – Shares | 15% |
| Retail Shares Offered | – Shares | 10% |
Veeda Clinical Research IPO Anchor Investors
| Anchor Bidding Date | 2025 |
| Anchor Investors List | |
| Shares Offered | – Shares |
| Anchor Size | – Cr. |
| lock-in period end date 50% shares (30 Days) | 2025 |
| lock-in period end date 50% shares (90 Days) | 2025 |
Veeda Clinical Research IPO Dates
The Veeda Clinical Research IPO date is 2025 and the close date is 2025. The Veeda Clinical Research IPO allotment will be finalized on 2025 and the IPO listing on 2025.
| IPO Open Date: | 2025 |
| IPO Close Date: | 2025 |
| Basis of Allotment: | 2025 |
| Refunds: | 2025 |
| Credit to Demat Account: | 2025 |
| IPO Listing Date: | 2025 |
| IPO Bidding Cut-off Time: | 2025 – 5 PM |
Promoters and Holding Pattern
The promoters of the company is Basil Private Limited.
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 6,57,77,495 | 33.83% |
| Promoter Holding Post Issue | – | -% |
Objects of the Issue & Utilisation of proceeds
| Purpose | Crores |
| Capital expenditure towards procurement of equipment and machinery for the Company | – |
| Investment in the Material Subsidiary, Bioneeds India Private Limited for capital expenditure towards procurement of equipment and machinery | – |
| Investment in the Material Subsidiary, Bioneeds India Private Limited, for repayment/pre-payment, in part or full of certain borrowings of theSubsidiary, Bioneeds India Private Limited; Funding organic growth of the Company, the Material Subsidiary, Bioneeds India Private Limited and Health Data Specialists (Holdings) Limited through marketing and promotional activities, updation of technology and adoption of modern digital solutions in our workflows to enhance the efficiency and quality assurance of the operating processes and data management; and | – |
| General corporate purposes. | – |
About Veeda Clinical IPO
Veeda Clinical Research Limited was established in April 2004, is one of the leading global full-service contract research organizations (“CRO”) in India. The company is involved in offering complete drug development services from pre-clinical testing to clinical trials for new drugs, generics, biosimilars, and medical devices.
Veeda Clinical is involved wide range of services, including (i) Clinical trials (early and late phase), (ii) Healthy volunteer studies like bioavailability and bioequivalence tests, (iii) Pre-clinical and non-clinical testing, and (iv) Biopharma services for large molecule analysis. Founded in 2004, and started its first facility in Ahmedabad, Gujarat, in 2005 with HVS capabilities. Since its incorporation, the company has been growing through expansion and acquisitions to help small, mid-sized, and global pharmaceutical companies.
Veeda Clinical Research IPO Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
| 2022 | ₹293.11 | ₹261.64 | ₹50.46 | ₹677.54 |
| 2023 | ₹420.21 | ₹358.06 | ₹42.42 | ₹734.77 |
| 2024 | ₹407.99 | ₹404.73 | ₹0.36 | ₹2,040.21 |
| September 2024 | ₹315.87 | ₹341.52 | ₹24.93 | ₹1,891.86 |
Veeda Clinical Research IPO Valuation – FY2024
Check Veeda Clinical Research IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | -% |
| ROCE: | -% |
| EBITDA Margin: | 18.32% |
| PAT Margin: | -% |
| Debt to equity ratio: | 0.32 |
| Earning Per Share (EPS): | ₹(0.04) (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | (0.02)% |
| Net Asset Value (NAV): | ₹189.04 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Sai Life Sciences Limited | 4.57 | 144.87 | 8.49% | 53.83 | 1,465.18 Cr. |
| Syngene International Limited | 12.71 | 58.87 | 23.99% | 231.29 | 3,488.60 Cr. |
| Vimta Labs Limited | 18.51 | 46.86 | 12.83 | 144.20 | 318.26 Cr. |
| Jeevan Scientific Technology Limited | (0.86) | (52.67) | 2.74 | 3.13 | 3.97 Cr. |
IPO Lead Managers aka Merchant Bankers
- Axis Capital Ltd.
- CLSA India Pvt.Ltd.
- IIFL Capital Services Ltd.
- SBI Capital Markets Ltd.
Company Address
Veeda Clinical Research Ltd.
Shivalik Plaza –A, 2nd Floor
Opposite Ahmedabad Management Association
Ambawadi
Ahmedabad, Gujarat, 380015
Phone: +91 79 6777 3000
Email: [email protected]
Website: https://veedalifesciences.com/
IPO Registrar
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: [email protected]
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Veeda Clinical Research IPO FAQs
What is Veeda Clinical Research IPO?
When Veeda Clinical Research IPO will open for subscription?
What is Veeda Clinical Research IPO Investors Portion?
How to Apply the Veeda Clinical Research IPO?
What is Veeda Clinical Research IPO Issue Size?
What is Veeda Clinical Research IPO Price Band?
What is Veeda Clinical Research IPO Lot Size?
What is the Veeda Clinical Research IPO Allotment Date?
What is the Veeda Clinical Research IPO Listing Date?
Note: The Veeda Clinical Research IPO price band and date are officially announced. The (Veeda Clinical Research IPO grey market premium) will be added to the IPO GMP page as it will start).
